New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-02

AUTHORS

Joëlle Egreteau, Eveline Boucher, Sophie de Guibert, Christian Jacquelinet, Bernard Meunier, Karim Boudjema, Jean-Luc Raoul

ABSTRACT

Background and Aims: Treatment of metastatic colorectal cancer with new drugs (NDs) as oxaliplatin and irinotecan had improved response and survival. In order to check whether the promising achievements of the trials are obtained in routine clinical practice, we have reviewed retrospectively our results for two periods, before (period A: 1993–1995, n=63) and after (period B: 1998–2000 n=103) the introduction of these NDs. Patients characteristics, treatment modalities, survival, and prognostic factors were compared.Patients: There were 74 women and 92 men, aged 60.8 ±11.6 yr, 7 patients received best supportive care only, 91 had synchronous metastasis.Results: Period B patients were older, with WHO score >1 more often, more adjuvant treatment, more metachronous metastasis, and NDs used more frequently (24% vs 59%). Median survival was similar (16 vs 15 mo). But when looking at the population aged <75 years with WHO score <2, median survival was 13 mo (period A) vs 21 mo (period B); survival at 1,2, and 3 yr were respectively 59.5±8%, 16.2±6%, 13.5±6% vs 69.8±6%, 49.6±7%, 29.8±7%, p<0.01). In multiparametric analysis, factors correlated with survival were the absence of elevated serum alkaline phosphatase, a unique metastatic organ, and administration of NDs.Conclusion: In our routine clinical experience the use of NDs for metastatic CRC has allowed a significant improvement in survival among patients with unresectable tumors. More... »

PAGES

69-76

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1385/ijgc:35:1:069

DOI

http://dx.doi.org/10.1385/ijgc:35:1:069

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043836884

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15722576


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Phytogenic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Evidence-Based Medicine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irinotecan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medical Oncology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxaliplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiophenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Egreteau", 
        "givenName": "Jo\u00eblle", 
        "id": "sg:person.0747070501.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747070501.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boucher", 
        "givenName": "Eveline", 
        "id": "sg:person.0665747347.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665747347.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Guibert", 
        "givenName": "Sophie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Etablissement Fran\u00e7ais des Greffes, 5 rue Lacu\u00e9, 75012, Paris", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Etablissement Fran\u00e7ais des Greffes, 5 rue Lacu\u00e9, 75012, Paris"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacquelinet", 
        "givenName": "Christian", 
        "id": "sg:person.0711624165.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711624165.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partement de Chirurgie Visc\u00e9rale, Chru Pontchaillou, 35033, Rennes Cedex, France", 
          "id": "http://www.grid.ac/institutes/grid.414271.5", 
          "name": [
            "D\u00e9partement de Chirurgie Visc\u00e9rale, Chru Pontchaillou, 35033, Rennes Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meunier", 
        "givenName": "Bernard", 
        "id": "sg:person.0613346173.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613346173.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partement de Chirurgie Visc\u00e9rale, Chru Pontchaillou, 35033, Rennes Cedex, France", 
          "id": "http://www.grid.ac/institutes/grid.414271.5", 
          "name": [
            "D\u00e9partement de Chirurgie Visc\u00e9rale, Chru Pontchaillou, 35033, Rennes Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boudjema", 
        "givenName": "Karim", 
        "id": "sg:person.01364777013.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364777013.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Oncologie M\u00e9dicale, Centre Eug\u00e8ne Marquis, 35042, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raoul", 
        "givenName": "Jean-Luc", 
        "id": "sg:person.0617474270.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617474270.02"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1998.421", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002229800", 
          "https://doi.org/10.1038/bjc.1998.421"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-02", 
    "datePublishedReg": "2005-02-01", 
    "description": "Background and Aims: Treatment of metastatic colorectal cancer with new drugs (NDs) as oxaliplatin and irinotecan had improved response and survival. In order to check whether the promising achievements of the trials are obtained in routine clinical practice, we have reviewed retrospectively our results for two periods, before (period A: 1993\u20131995, n=63) and after (period B: 1998\u20132000 n=103) the introduction of these NDs. Patients characteristics, treatment modalities, survival, and prognostic factors were compared.Patients: There were 74 women and 92 men, aged 60.8 \u00b111.6 yr, 7 patients received best supportive care only, 91 had synchronous metastasis.Results: Period B patients were older, with WHO score >1 more often, more adjuvant treatment, more metachronous metastasis, and NDs used more frequently (24% vs 59%). Median survival was similar (16 vs 15 mo). But when looking at the population aged <75 years with WHO score <2, median survival was 13 mo (period A) vs 21 mo (period B); survival at 1,2, and 3 yr were respectively 59.5\u00b18%, 16.2\u00b16%, 13.5\u00b16% vs 69.8\u00b16%, 49.6\u00b17%, 29.8\u00b17%, p<0.01). In multiparametric analysis, factors correlated with survival were the absence of elevated serum alkaline phosphatase, a unique metastatic organ, and administration of NDs.Conclusion: In our routine clinical experience the use of NDs for metastatic CRC has allowed a significant improvement in survival among patients with unresectable tumors.", 
    "genre": "article", 
    "id": "sg:pub.10.1385/ijgc:35:1:069", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297362", 
        "issn": [
          "1941-6628", 
          "1941-6636"
        ], 
        "name": "Journal of Gastrointestinal Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "median survival", 
      "new drugs", 
      "colorectal cancer", 
      "elevated serum alkaline phosphatase", 
      "metastatic colorectal cancer", 
      "routine clinical practice", 
      "serum alkaline phosphatase", 
      "routine clinical experience", 
      "supportive care", 
      "synchronous metastases", 
      "adjuvant treatment", 
      "B patients", 
      "patient characteristics", 
      "prognostic factors", 
      "metachronous metastases", 
      "metastatic CRC", 
      "unresectable tumors", 
      "metastatic organs", 
      "treatment modalities", 
      "clinical experience", 
      "clinical practice", 
      "routine practice", 
      "patients", 
      "survival", 
      "metastasis", 
      "cancer", 
      "alkaline phosphatase", 
      "drugs", 
      "treatment", 
      "significant improvement", 
      "multiparametric analysis", 
      "irinotecan", 
      "oxaliplatin", 
      "tumors", 
      "administration", 
      "trials", 
      "yr", 
      "women", 
      "care", 
      "CRC", 
      "men", 
      "modalities", 
      "factors", 
      "organs", 
      "aim", 
      "population", 
      "years", 
      "response", 
      "practice", 
      "period", 
      "phosphatase", 
      "absence", 
      "Mo", 
      "background", 
      "improvement", 
      "experience", 
      "use", 
      "results", 
      "analysis", 
      "promising achievements", 
      "characteristics", 
      "introduction", 
      "expectations", 
      "achievement", 
      "order", 
      "Period B patients", 
      "unique metastatic organ", 
      "administration of NDs", 
      "use of NDs"
    ], 
    "name": "New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice", 
    "pagination": "69-76", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043836884"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1385/ijgc:35:1:069"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15722576"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1385/ijgc:35:1:069", 
      "https://app.dimensions.ai/details/publication/pub.1043836884"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_411.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1385/ijgc:35:1:069"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1385/ijgc:35:1:069'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1385/ijgc:35:1:069'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1385/ijgc:35:1:069'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1385/ijgc:35:1:069'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      22 PREDICATES      119 URIs      110 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1385/ijgc:35:1:069 schema:about N01fda0a02260416a805ced14a1158d57
2 N147717ec0e3c41828af867fde6a82820
3 N1785f63c88b8456eb7a844d1bafaf3a8
4 N253867205d7b4180832fb6b024ed40ea
5 N3586a6af20e0401f9671e0c728125b0a
6 N3668192ef555467098b3690e4cae4036
7 N3d714c9ac6384c75a1b4bb6a1f31adac
8 N55d44a4a13fe430ba53bef97900de55d
9 N846608030edd4eb7ae9f54203994042a
10 N8707674620184eb0b9699e50920c1e63
11 Na6c573d90c3e411398ad071bc97e8ec6
12 Nb54269673d2f4d2092d97eaffc39b18d
13 Nbbdbf178e197481e8a880a4b34b511d8
14 Nc75ecc17b3f74c80965705a048405874
15 Nd6137eeff1874f42b9e615ba55b273aa
16 Ne0416185d6a9477b982a7b4ff6d6517a
17 Ne12dcc383f384680aa38dd9dff2393c3
18 Ne2b8e14bbd5f432eb712b940c59abe00
19 Neeed02288cbd49b6882767bf69a7eede
20 Nf097b7061ae1446abc01d7c5699c30a6
21 Nfcbe49ff4fdb455fb2408002d5c924ef
22 Nff6a1185f45f45268eea5ece8b381527
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author Nba9f81261ce44fdbad5946e29e00d6eb
26 schema:citation sg:pub.10.1038/bjc.1998.421
27 schema:datePublished 2005-02
28 schema:datePublishedReg 2005-02-01
29 schema:description Background and Aims: Treatment of metastatic colorectal cancer with new drugs (NDs) as oxaliplatin and irinotecan had improved response and survival. In order to check whether the promising achievements of the trials are obtained in routine clinical practice, we have reviewed retrospectively our results for two periods, before (period A: 1993–1995, n=63) and after (period B: 1998–2000 n=103) the introduction of these NDs. Patients characteristics, treatment modalities, survival, and prognostic factors were compared.Patients: There were 74 women and 92 men, aged 60.8 ±11.6 yr, 7 patients received best supportive care only, 91 had synchronous metastasis.Results: Period B patients were older, with WHO score >1 more often, more adjuvant treatment, more metachronous metastasis, and NDs used more frequently (24% vs 59%). Median survival was similar (16 vs 15 mo). But when looking at the population aged <75 years with WHO score <2, median survival was 13 mo (period A) vs 21 mo (period B); survival at 1,2, and 3 yr were respectively 59.5±8%, 16.2±6%, 13.5±6% vs 69.8±6%, 49.6±7%, 29.8±7%, p<0.01). In multiparametric analysis, factors correlated with survival were the absence of elevated serum alkaline phosphatase, a unique metastatic organ, and administration of NDs.Conclusion: In our routine clinical experience the use of NDs for metastatic CRC has allowed a significant improvement in survival among patients with unresectable tumors.
30 schema:genre article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf N0ddf8d8d2b2b4ba9bbb98dbdc4ee8217
34 Nf8862ab134e9424b81b91528de83a6f6
35 sg:journal.1297362
36 schema:keywords B patients
37 CRC
38 Mo
39 Period B patients
40 absence
41 achievement
42 adjuvant treatment
43 administration
44 administration of NDs
45 aim
46 alkaline phosphatase
47 analysis
48 background
49 cancer
50 care
51 characteristics
52 clinical experience
53 clinical practice
54 colorectal cancer
55 drugs
56 elevated serum alkaline phosphatase
57 expectations
58 experience
59 factors
60 improvement
61 introduction
62 irinotecan
63 median survival
64 men
65 metachronous metastases
66 metastasis
67 metastatic CRC
68 metastatic colorectal cancer
69 metastatic organs
70 modalities
71 multiparametric analysis
72 new drugs
73 order
74 organs
75 oxaliplatin
76 patient characteristics
77 patients
78 period
79 phosphatase
80 population
81 practice
82 prognostic factors
83 promising achievements
84 response
85 results
86 routine clinical experience
87 routine clinical practice
88 routine practice
89 serum alkaline phosphatase
90 significant improvement
91 supportive care
92 survival
93 synchronous metastases
94 treatment
95 treatment modalities
96 trials
97 tumors
98 unique metastatic organ
99 unresectable tumors
100 use
101 use of NDs
102 women
103 years
104 yr
105 schema:name New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice
106 schema:pagination 69-76
107 schema:productId N01e38199a62b4a97955ebc4886242e31
108 N7d7dff591878482294ea50a304d434b4
109 Nb37f575208f542ea845a4077bd226868
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043836884
111 https://doi.org/10.1385/ijgc:35:1:069
112 schema:sdDatePublished 2022-01-01T18:15
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher N52b36e65e2464c649f3b20bb2603418c
115 schema:url https://doi.org/10.1385/ijgc:35:1:069
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N01e38199a62b4a97955ebc4886242e31 schema:name dimensions_id
120 schema:value pub.1043836884
121 rdf:type schema:PropertyValue
122 N01fda0a02260416a805ced14a1158d57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Antineoplastic Agents
124 rdf:type schema:DefinedTerm
125 N0ddf8d8d2b2b4ba9bbb98dbdc4ee8217 schema:issueNumber 1
126 rdf:type schema:PublicationIssue
127 N147717ec0e3c41828af867fde6a82820 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Evidence-Based Medicine
129 rdf:type schema:DefinedTerm
130 N1785f63c88b8456eb7a844d1bafaf3a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Quinazolines
132 rdf:type schema:DefinedTerm
133 N253867205d7b4180832fb6b024ed40ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Thiophenes
135 rdf:type schema:DefinedTerm
136 N3586a6af20e0401f9671e0c728125b0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Survival Analysis
138 rdf:type schema:DefinedTerm
139 N3668192ef555467098b3690e4cae4036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Retrospective Studies
141 rdf:type schema:DefinedTerm
142 N3d714c9ac6384c75a1b4bb6a1f31adac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Oxaliplatin
144 rdf:type schema:DefinedTerm
145 N52b36e65e2464c649f3b20bb2603418c schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 N55a3ba3fe57a4710bf2a851837846d50 rdf:first sg:person.0711624165.16
148 rdf:rest Nd32f565a3fd941e3b05d6731a831d6b4
149 N55d44a4a13fe430ba53bef97900de55d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Organoplatinum Compounds
151 rdf:type schema:DefinedTerm
152 N646bbb670c5b45d28a7b69aa4569dc69 schema:affiliation grid-institutes:grid.417988.b
153 schema:familyName de Guibert
154 schema:givenName Sophie
155 rdf:type schema:Person
156 N7d7dff591878482294ea50a304d434b4 schema:name pubmed_id
157 schema:value 15722576
158 rdf:type schema:PropertyValue
159 N846608030edd4eb7ae9f54203994042a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Camptothecin
161 rdf:type schema:DefinedTerm
162 N8707674620184eb0b9699e50920c1e63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Medical Oncology
164 rdf:type schema:DefinedTerm
165 N9174facb87294cf2bceef0e5fee73385 rdf:first sg:person.0665747347.57
166 rdf:rest Ndefafe4ed9f44bcb83f91fe2d903bce0
167 Na595ba2efcdd4c9abf5dac34bb818a7a rdf:first sg:person.01364777013.76
168 rdf:rest Nbd9fa04575a444cd97c2e3f187202a51
169 Na6c573d90c3e411398ad071bc97e8ec6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Colorectal Neoplasms
171 rdf:type schema:DefinedTerm
172 Nb37f575208f542ea845a4077bd226868 schema:name doi
173 schema:value 10.1385/ijgc:35:1:069
174 rdf:type schema:PropertyValue
175 Nb54269673d2f4d2092d97eaffc39b18d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Female
177 rdf:type schema:DefinedTerm
178 Nba9f81261ce44fdbad5946e29e00d6eb rdf:first sg:person.0747070501.13
179 rdf:rest N9174facb87294cf2bceef0e5fee73385
180 Nbbdbf178e197481e8a880a4b34b511d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Antineoplastic Agents, Phytogenic
182 rdf:type schema:DefinedTerm
183 Nbd9fa04575a444cd97c2e3f187202a51 rdf:first sg:person.0617474270.02
184 rdf:rest rdf:nil
185 Nc75ecc17b3f74c80965705a048405874 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Irinotecan
187 rdf:type schema:DefinedTerm
188 Nd32f565a3fd941e3b05d6731a831d6b4 rdf:first sg:person.0613346173.33
189 rdf:rest Na595ba2efcdd4c9abf5dac34bb818a7a
190 Nd6137eeff1874f42b9e615ba55b273aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Aged
192 rdf:type schema:DefinedTerm
193 Ndefafe4ed9f44bcb83f91fe2d903bce0 rdf:first N646bbb670c5b45d28a7b69aa4569dc69
194 rdf:rest N55a3ba3fe57a4710bf2a851837846d50
195 Ne0416185d6a9477b982a7b4ff6d6517a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Middle Aged
197 rdf:type schema:DefinedTerm
198 Ne12dcc383f384680aa38dd9dff2393c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Humans
200 rdf:type schema:DefinedTerm
201 Ne2b8e14bbd5f432eb712b940c59abe00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Male
203 rdf:type schema:DefinedTerm
204 Neeed02288cbd49b6882767bf69a7eede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Treatment Outcome
206 rdf:type schema:DefinedTerm
207 Nf097b7061ae1446abc01d7c5699c30a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Age Factors
209 rdf:type schema:DefinedTerm
210 Nf8862ab134e9424b81b91528de83a6f6 schema:volumeNumber 35
211 rdf:type schema:PublicationVolume
212 Nfcbe49ff4fdb455fb2408002d5c924ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Antimetabolites, Antineoplastic
214 rdf:type schema:DefinedTerm
215 Nff6a1185f45f45268eea5ece8b381527 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Prognosis
217 rdf:type schema:DefinedTerm
218 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
219 schema:name Medical and Health Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
222 schema:name Oncology and Carcinogenesis
223 rdf:type schema:DefinedTerm
224 sg:journal.1297362 schema:issn 1941-6628
225 1941-6636
226 schema:name Journal of Gastrointestinal Cancer
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01364777013.76 schema:affiliation grid-institutes:grid.414271.5
230 schema:familyName Boudjema
231 schema:givenName Karim
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364777013.76
233 rdf:type schema:Person
234 sg:person.0613346173.33 schema:affiliation grid-institutes:grid.414271.5
235 schema:familyName Meunier
236 schema:givenName Bernard
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613346173.33
238 rdf:type schema:Person
239 sg:person.0617474270.02 schema:affiliation grid-institutes:grid.417988.b
240 schema:familyName Raoul
241 schema:givenName Jean-Luc
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617474270.02
243 rdf:type schema:Person
244 sg:person.0665747347.57 schema:affiliation grid-institutes:grid.417988.b
245 schema:familyName Boucher
246 schema:givenName Eveline
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665747347.57
248 rdf:type schema:Person
249 sg:person.0711624165.16 schema:affiliation grid-institutes:None
250 schema:familyName Jacquelinet
251 schema:givenName Christian
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711624165.16
253 rdf:type schema:Person
254 sg:person.0747070501.13 schema:affiliation grid-institutes:grid.417988.b
255 schema:familyName Egreteau
256 schema:givenName Joëlle
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747070501.13
258 rdf:type schema:Person
259 sg:pub.10.1038/bjc.1998.421 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002229800
260 https://doi.org/10.1038/bjc.1998.421
261 rdf:type schema:CreativeWork
262 grid-institutes:None schema:alternateName Etablissement Français des Greffes, 5 rue Lacué, 75012, Paris
263 schema:name Etablissement Français des Greffes, 5 rue Lacué, 75012, Paris
264 rdf:type schema:Organization
265 grid-institutes:grid.414271.5 schema:alternateName Département de Chirurgie Viscérale, Chru Pontchaillou, 35033, Rennes Cedex, France
266 schema:name Département de Chirurgie Viscérale, Chru Pontchaillou, 35033, Rennes Cedex, France
267 rdf:type schema:Organization
268 grid-institutes:grid.417988.b schema:alternateName Oncologie Médicale, Centre Eugène Marquis, 35042, Rennes, France
269 schema:name Oncologie Médicale, Centre Eugène Marquis, 35042, Rennes, France
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...